or Try an Advanced Search...

    ETF Components for OZEM - Roundhill GLP-1 & Weight Loss ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    NVO D -2.81 17.04
    LLY F -1.03 14.13
    ALT C 7.89 4.44
    AZN F 1.00 3.99
    VKTX F 1.80 3.39
    AMGN D 0.03 3.26
    PFE F -0.04 3.07
    SRRK B -6.68 2.80
    REGN F 0.42 2.40
    RYTM C -0.30 2.30
    TAK D 0.04 2.17
    TERN F 1.79 1.97
    CORT B 1.00 1.77
    OPK B -0.63 1.72

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Obesity Pharmaceutical Products Cancer Inflammation Biotechnology Diabetes Medicine Neuroscience S&P 500 Alzheimer's Disease Anemia Asthma Cholesterol Depressive Disorder Hormones Hypertension Life Sciences Major Depressive Disorder Medication
    Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic

    Recent News for Roundhill GLP-1 & Weight Loss ETF & its Holdings

    Date Stock Title
    Nov 21 PFE Major companies that are also popular short-selling stocks
    Nov 21 PFE The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
    Nov 21 PFE Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
    Nov 21 PFE 2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
    Nov 21 AZN We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
    Nov 21 AMGN Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares
    Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
    Nov 21 AZN 3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
    Nov 21 AMGN Amgen picks prolific biotech founder Chang as new top scientist
    Nov 21 AZN AstraZeneca upgraded to Neutral from Sell at UBS
    Nov 21 PFE EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
    Nov 21 AZN AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg
    Nov 21 PFE 2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
    Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
    Nov 21 AMGN Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
    Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
    Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
    Nov 20 PFE CDC warns of an imminent spike in COVID, flu cases
    Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
    Nov 20 PFE 5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
    OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
    Weight Management Peptide Therapeutics
    Back to the Main OZEM Page...